Subscribe

Sinopharm Group Co. Ltd. (1099.HK)

HKD17.01 +0.16 (+0.95%)
CN HKSE Healthcare Medical - Distribution
Address Sinopharm Group Building 200023
Shanghai, CN
CEO Wanyong Lian
Website sinopharmgroup.com.cn
IPO 2009-09-23
ISIN CNE100000FN7

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 1099.HK (HKD) Other OTC · SHTDF (USD) Other OTC · SHTDY (USD)
Description

Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD17.01 +0.16 (+0.95%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.45
Float Shares
1.34B
Free Float %
43.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.12% -4.94% -8.39% -19.96% -15.57% -12.96% -10.95% -34.04% -35.91% -52.54% -8.64%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
17.01
DCF (Levered) 198.68 +1,068.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 77% Bullish
Rating 2026-05 Change
Strong Buy 4 0
Buy 6 0
Hold 3 -1
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.89
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Distribution: +5.6%
    -1.6% Q4'25: -2.2% (vs Q4'23)
  • ✓
    EPS growth Medical - Distribution: +4.9%
    +1.3% Q4'25: -25.8% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Distribution: +37.6%
    +1.5% Q4'25: +15.7% (vs Q4'23)
  • ✗
    EBIT margin Medical - Distribution: +3.0%
    +3.0% Q4'25: +3.3% (vs Q4'23)
  • ✗
    ROIC Medical - Distribution: +5.7%
    +7.0% ★ Q4'25: +15.2% (vs Q4'23)
  • ✓
    Share dilution Medical - Distribution: +0.0%
    +0.0% Q4'25: +0.1% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×
    5.64× Q4'25: 2.60× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.48) × ERP
WACC = 30% × Ke + 70% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 17.01
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2009
actual 		Dec 2010
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
11 Rev. Ana.
11 EPS Ana. 		Dec 2027
13 Rev. Ana.
11 EPS Ana. 		Dec 2028
9 Rev. Ana.
8 EPS Ana.
Revenue
47.05B
est: 46.78B (+0.6%)
69.23B
est: 65.84B (+5.2%)
102.22B
est: 100.65B (+1.6%)
135.79B
est: 133.56B (+1.7%)
166.87B
est: 166.09B (+0.5%)
200.13B
est: 202.47B (-1.2%)
228.67B
est: 230.88B (-1.0%)
258.12B
est: 257.51B (+0.2%)
277.03B
est: 285.11B (-2.8%)
344.53B
est: 298.78B (+15.3%)
425.27B
est: 402.73B (+5.6%)
456.41B
est: 456.62B (0.0%)
521.05B
est: 526.59B (-1.1%)
552.15B
est: 561.84B (-1.7%)
596.57B
est: 549.14B (+8.6%)
584.51B
est: 598.68B (-2.4%)
575.17B
est: 582.31B (-1.2%)
614.95B
599.57B – 628.49B
+5.6% YoY
643.32B
599.52B – 681.74B
+4.6% YoY
676.20B
644.34B – 704.18B
+5.1% YoY
EBITDA
2.01B
est: 2.10B (-3.9%)
3.05B
est: 1.85B (+65.1%)
4.43B
est: 3.06B (+44.9%)
5.91B
est: 2.96B (+99.4%)
6.70B
est: 3.09B (+117.0%)
8.61B
est: 3.12B (+175.7%)
10.13B
est: 3.75B (+169.7%)
12.04B
est: 5.33B (+125.9%)
13.43B
est: 6.86B (+95.8%)
16.67B
est: 8.21B (+103.1%)
20.32B
est: 9.65B (+110.6%)
22.62B
est: 11.76B (+92.4%)
24.68B
est: 13.29B (+85.8%)
26.25B
est: 14.61B (+79.7%)
26.90B
est: 22.85B (+17.7%)
20.17B
est: 24.97B (-19.2%)
19.26B
est: 24.23B (-20.5%)
25.58B
24.94B – 26.15B
+5.6% YoY
26.76B
24.94B – 28.36B
+4.6% YoY
28.13B
26.81B – 29.29B
+5.1% YoY
EBIT
2.17B
est: 1.77B (+22.1%)
2.75B
est: 2.25B (+21.8%)
3.97B
est: 3.68B (+7.9%)
5.34B
est: 4.82B (+10.7%)
6.35B
est: 6.05B (+4.9%)
8.13B
est: 7.44B (+9.2%)
9.56B
est: 9.14B (+4.6%)
10.97B
est: 10.27B (+6.8%)
14.02B
est: 11.40B (+23.1%)
15.28B
est: 14.71B (+3.9%)
17.20B
est: 20.38B (-15.6%)
19.02B
est: 17.98B (+5.8%)
20.76B
est: 20.32B (+2.2%)
22.08B
est: 22.34B (-1.2%)
22.47B
est: 19.54B (+15.0%)
17.82B
est: 21.36B (-16.6%)
17.23B
est: 20.72B (-16.9%)
21.89B
21.34B – 22.37B
+5.6% YoY
22.89B
21.34B – 24.26B
+4.6% YoY
24.07B
22.93B – 25.06B
+5.1% YoY
Net Income
845.82M
est: 1.21B (-30.3%)
1.21B
est: 1.19B (+1.5%)
1.56B
est: 1.85B (-15.6%)
1.97B
est: 2.07B (-4.7%)
2.25B
est: 2.45B (-8.3%)
2.87B
est: 2.74B (+4.8%)
3.76B
est: 3.34B (+12.7%)
4.65B
est: 4.17B (+11.3%)
7.87B
est: 5.11B (+53.9%)
9.40B
est: 6.14B (+53.2%)
10.62B
est: 7.72B (+37.5%)
7.19B
est: 7.02B (+2.4%)
7.76B
est: 7.93B (-2.2%)
8.53B
est: 8.72B (-2.2%)
9.05B
est: 8.05B (+12.5%)
7.05B
est: 8.10B (-12.9%)
7.16B
est: 7.37B (-2.9%)
8.25B
7.29B – 9.21B
+11.9% YoY
8.77B
7.59B – 9.95B
+6.3% YoY
9.99B
8.12B – 11.85B
+13.9% YoY
SGA
2.29B
est: 2.09B (+9.3%)
3.50B
est: 3.22B (+8.9%)
4.89B
est: 5.18B (-5.6%)
6.30B
est: 5.97B (+5.4%)
7.59B
est: 7.11B (+6.6%)
8.68B
est: 9.04B (-4.0%)
9.75B
est: 10.06B (-3.1%)
10.73B
est: 10.77B (-0.4%)
11.57B
est: 11.80B (-2.0%)
15.89B
est: 13.52B (+17.5%)
19.47B
est: 19.54B (-0.3%)
21.19B
est: 20.73B (+2.2%)
23.20B
est: 23.43B (-1.0%)
24.90B
est: 25.76B (-3.3%)
26.15B
est: 24.05B (+8.7%)
25.57B
est: 26.28B (-2.7%)
24.02B
est: 25.50B (-5.8%)
26.93B
26.26B – 27.52B
+5.6% YoY
28.17B
26.26B – 29.86B
+4.6% YoY
29.61B
28.22B – 30.84B
+5.1% YoY
EPS
0.53
est: 0.39 (+36.3%)
0.53
est: 0.49 (+7.8%)
0.66
est: 0.55 (+20.6%)
0.82
est: 0.66 (+24.6%)
0.89
est: 0.74 (+20.5%)
1.11
est: 0.89 (+25.2%)
1.36
est: 1.32 (+2.7%)
1.68
est: 1.69 (-0.4%)
2.65
est: 1.83 (+44.5%)
3.17
est: 1.96 (+61.8%)
3.58
est: 2.10 (+70.4%)
2.31
est: 2.25 (+2.7%)
2.49
est: 2.58 (-3.4%)
2.73
est: 2.68 (+2.0%)
2.90
est: 2.58 (+12.3%)
2.26
est: 2.60 (-13.2%)
2.29
est: 2.37 (-3.4%)
2.52
2.34 – 2.95
+6.4% YoY
2.73
2.43 – 3.19
+8.3% YoY
2.98
2.60 – 3.80
+9.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-28 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-27 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-26 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-22 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-21 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-20 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-19 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-18 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-15 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-14 A- 4/5 5/5 4/5 4/5 1/5 3/5 4/5
2026-05-13 A 4/5 5/5 4/5 4/5 1/5 3/5 5/5
2026-05-12 A 4/5 5/5 4/5 4/5 1/5 3/5 5/5
2026-05-11 A 4/5 5/5 4/5 4/5 1/5 3/5 5/5
2026-05-08 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-05-07 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-05-06 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-05-05 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-05-04 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-04-30 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-04-29 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-04-28 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-04-27 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-04-24 A 4/5 5/5 3/5 4/5 1/5 4/5 5/5
2026-04-23 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-04-22 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-04-21 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-04-20 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-04-17 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-04-16 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-04-15 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
25.02B
OE per share TTM
8.04
Owner's Yield
47.26%
Maintenance CapEx ratio
29.83%
Maint CapEx / Avg PPE
3.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
159.2K
Shares Outstanding
3.12B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Binghua Yang Executive Director 3M male
Wanyong Lian President & Executive Director 2M male
Xiaojuan Li Chief Financial Officer — female
Yijian Wu Vice President, Secretary to the Board & Company Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Distribution